Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
Suven Pharmaceuticals Financial Highlights
- Revenue: Suven Pharmaceuticals reported revenue of ₹2,302.64 crore in FY26 vs ₹2,677.71 crore in FY25. It showed a decrease of 14.01% on a yearly basis.
- Operating Profit: Suven Pharmaceuticals reported an operating profit of ₹207.04 crore in FY26 vs ₹642.63 crore in FY25. It showed a decrease of 67.78% on a year-on-year basis.
- Net Profit: Suven Pharmaceuticals reported a net profit of ₹150.12 crore in FY26 vs ₹484.24 crore in FY25. It showed a decrease of 69.00% on a yearly basis.
Suven Pharmaceuticals Quarterly Result Highlights
- Suven Pharmaceuticals reported revenue of ₹617.28 crore in Mar 2026, compared with ₹550.71 crore in Dec 2025, representing an increase of 12.09% on a quarter-on-quarter (QoQ) basis.
- Suven Pharmaceuticals reported an operating profit of ₹19.91 crore in Mar 2026, compared with ₹40.60 crore in Dec 2025, representing a decrease of 50.96% on a quarter-on-quarter (QoQ) basis.
- Suven Pharmaceuticals reported a profit of ₹8.31 crore in Mar 2026, compared with ₹29.02 crore in Dec 2025, reflecting a decrease of 71.36% on a QoQ basis.
- The earnings per share (EPS) of Suven Pharmaceuticals stood at ₹10.52 during Mar 2026.
